Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

973.12 +38.52 (+4.12%)
Streaming Delayed Price Updated: 9:37 AM EDT, May 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
99 100 Next >
News headline image
AlphaFold’s Five-Year Reign: 3 Million Researchers and the Dawn of a New Biological Era
In a milestone that cements artificial intelligence as the most potent tool in modern science, Google DeepMind’s AlphaFold has officially surpassed 3 million users worldwide. This achievement coincides... 
Via TokenRing AI
Topics Artificial Intelligence Climate Change
News headline image
The 2026 Horizon: Wall Street Bets on the 'Application Era' and the Nuclear Renaissance
As the final trading days of 2025 come to a close, Wall Street is pivoting its focus from the hardware-driven "AI Gold Rush" toward a 2026 outlook defined by practical utility, autonomous software, and... 
Via MarketMinute
Topics Artificial Intelligence Economy Energy
News headline image
The Great Rebalancing: Investors Pivot Away from Big Tech as 2026 Looms
As the final trading days of 2025 wind down, a massive tactical shift is sweeping through Wall Street. Institutional fund managers and retail investors alike are aggressively rebalancing portfolios,... 
Via MarketMinute
Topics Artificial Intelligence Bonds ETFs
News headline image
The Great Pivot: Navigating the Rollercoaster 2025 Market as the Final Bell Approaches
As the sun sets on December 29, 2025, the U.S. stock market stands at a historic crossroads, capping off a year defined by extreme volatility, political brinkmanship, and a definitive shift in monetary... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
S&P 500 Tests Resilience: Technical Pullback Follows Historic Record Highs as 2025 Draws to a Close
The S&P 500 (NYSE:SPY) entered the final week of 2025 in uncharted territory, having notched a series of historic closing records that culminated in a Christmas Eve milestone. However, as the calendar... 
Via MarketMinute
Topics Artificial Intelligence Economy Stocks
News headline image
The Trillion-Dollar Apothecary: Inside Eli Lilly’s Era of Metabolic Dominance
As of late 2025, the global pharmaceutical landscape has undergone a tectonic shift, and at its center stands Eli Lilly and Company (NYSE: LLY). Once regarded as a steady, dividend-paying stalwart of... 
Via PredictStreet
Topics Earnings Economy Intellectual Property
News headline image
This Beaten-Down Stock Just Jumped By 8%. Time to Buy? ↗
Is this the start of a sustained run for the Danish drugmaker? 
Via The Motley Fool
News headline image
Eli Lilly & Co (NYSE:LLY) Stands Out as a Secure Dividend Growth Stock ↗
Eli Lilly (LLY) offers a secure, growing dividend supported by strong profitability and financial health, ideal for a dividend growth investment strategy. 
Via Chartmill
News headline image
Novo Nordisk Slashes Weight Loss Drug Price By Up To 50% In China: Report ↗
Prices of Wegovy’s two highest doses were reduced to 987.48 yuan ($141) and 1,284.36 yuan, according to a Bloomberg article on Monday, citing Yicai. 
Via Stocktwits
Topics Intellectual Property
News headline image
The Weight Loss Drug Competition Is Heating Up: These 2 Industry Leaders Just Filed Competing Drugs with the FDA. ↗
Other drugmakers seem to be too far behind to disrupt this duopoly, at least for now. 
Via The Motley Fool
News headline image
1 Stock Under $50 on Our Buy List and 2 We Find Risky
The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to... 
Via StockStory
Topics Economy
News headline image
Reflecting On Pharmaceuticals Stocks’ Q3 Earnings: Jazz Pharmaceuticals (NASDAQ:JAZZ)
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the pharmaceuticals stocks, including Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Drug Stocks to Buy at a Discount ↗
The GLP-1 fight just entered a new round, and it highlights why these three out-of-favor drug makers are worth a deep dive. 
Via The Motley Fool
Topics Intellectual Property
News headline image
The Best Stocks to Invest $50,000 in Right Now ↗
If you're investing for the long run, there are a myriad of companies begging to be bought. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Here Are My Top 3 Growth Stocks to Buy Now ↗
These profitable businesses have plenty of room left to run. 
Via The Motley Fool
News headline image
Should You Invest in Ozempic Maker Novo Nordisk in 2026? ↗
The pharmaceutical giant's stock has tumbled over the past year and a half, but it could be poised to storm back. 
Via The Motley Fool
News headline image
Eli Lilly’s New Drug Data Sets Up a High-Stakes 2026 ↗
Via MarketBeat
News headline image
The Ghost Town Effect: How Thin Holiday Liquidity is Jolting US Equities
The halls of the New York Stock Exchange are quiet as the final week of 2025 unfolds, but the price tickers are anything but calm. Following the Christmas holiday, the U.S. stock market has entered its... 
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
Sector Rotation: 2 Smart Money Moves for 2026 ↗
Via MarketBeat
News headline image
This Smallcap Pharma Stock Is Gaining Retail Buzz Ahead Of A Key FDA Ruling ↗
The FDA is expected to issue a decision on Vanda’s Tradipitant, a motion-sickness treatment aimed at preventing vomiting, on Dec. 30, 2025. 
Via Stocktwits
News headline image
Buying This Pharmaceutical Stock Could Make You a Millionaire Retiree ↗
A key product portfolio is bringing in blockbuster revenue. 
Via The Motley Fool
News headline image
The Biological Turing Point: How AlphaFold 3 and the Nobel Prize Redefined the Future of Medicine
In the final weeks of 2025, the scientific community is reflecting on a year where the boundary between computer science and biology effectively vanished. The catalyst for this transformation was... 
Via TokenRing AI
Topics Artificial Intelligence Initial Public Offering
News headline image
The Great Broadening: How AI Implementation Reshaped the Non-Tech Bottom Line in 2025
As the curtain closes on 2025, the narrative that dominated Wall Street for the past three years has undergone a fundamental transformation. What began as a speculative frenzy centered around silicon... 
Via MarketMinute
Topics Artificial Intelligence Economy Fraud
News headline image
Is Eli Lilly Pulling Ahead in the Weight Loss Drug Battle? ↗
It's a two-horse race right now, sort of. 
Via The Motley Fool
News headline image
Pfizer’s 2026 Outlook Misses the Mark as Post-Pandemic Hangover and Patent Cliff Loom
NEW YORK — On December 16, 2025, Pfizer (NYSE:PFE) issued a conservative financial outlook for the 2026 fiscal year, falling short of Wall Street’s expectations and signaling a prolonged period of... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
The Oral Revolution: Novo Nordisk’s High-Stakes Bet on the Wegovy Pill
Introduction As of December 25, 2025, the global pharmaceutical landscape is witnessing a seismic shift centered on a single Danish company: Novo Nordisk (NYSE: NVO). Long the undisputed king of the... 
Via PredictStreet
Topics Economy Intellectual Property World Trade
News headline image
The Vaccine Vanguard: Inside Sanofi’s $2.2 Billion Strategic Bet on Dynavax
As 2025 draws to a close, the global pharmaceutical landscape has been reshaped by a series of aggressive consolidations and strategic pivots. At the center of this transformation is Sanofi (NASDAQ:... 
Via PredictStreet
Topics Artificial Intelligence Economy Intellectual Property
News headline image
The Trillion-Dollar Pharma: A Deep Dive into Eli Lilly’s (LLY) Dominance in the Weight-Loss Era
As of December 25, 2025, the global pharmaceutical landscape has been fundamentally reshaped by a single entity: Eli Lilly and Company (NYSE: LLY). In a year defined by breakthrough medical treatments... 
Via PredictStreet
Topics Economy Government Intellectual Property
News headline image
As the FDA Approves a Wegovy Pill, Should You Buy, Sell, or Hold Novo Nordisk Stock?
As Novo Nordisk’s FDA-approved Wegovy pill sets up a high-stakes comeback, should NVO be back on investors’ radar now? 
Via Barchart.com
Topics Workforce
News headline image
Eli Lilly & Co (NYSE:LLY) Presents a Compelling Growth at a Reasonable Price (GARP) Case ↗
Eli Lilly (LLY) exemplifies Growth at a Reasonable Price (GARP) with top-tier earnings, strong expansion, and a valuation balanced against its industry-leading growth outlook. 
Via Chartmill
< Previous 1 2
...
24 25 26 27 28 29 30 31 32
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.